Hint mode is switched on Switch off
For swift navigation between sections

PTC Therapeutics
LEI 549300UJLWOIWFDGB318

PDF download

Choose all Reset all
Download Cancel
Organization name
PTC Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
288 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

PTC Therapeutics is a US pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases.

Awards

News

08/05/2026 PTC Therapeutics (PTCT) Beats Q1, Raises 2026 Revenue Guidance
24/03/2026 PTC Therapeutics: Regulation Fd Disclosure, Financial Statements And Exhibits
19/02/2026 PTC Therapeutics: Item7.01.regulation Fd Disclosure, Regulation Fd Disclosure, Financial Statements And Exhibits
12/02/2026 PTC Therapeutics: Of This Report, Including Exhibit 99.1 Shall Not Be Deemed “filed” For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the “exchange Act”), Or Otherwise Subject To The Liabilities Of That Section, Nor Shall It Be Deemed Incorporated By Reference In Any Filing Under The Securities Act Of 1933, As Amended, Or The Exchange Act, Except As Expressly Set Forth By Specific Reference In Such A Filing. All Website Addresses Given In This Report Or Incorporated Herein By Reference Are For Information Only And Are Not Intended To Be An Active Link Or To Incorporate Any Website Information Into This Report, Financial Statements And Exhibits
12/01/2026 PTC Therapeutics: This Current Report On Form 8k And Exhibits 99.1 And 99.2 Include A Forwardlooking Financial Measure That Was Not Prepared In Accordance With Accounting Principles Generally Accepted In The United States (gaap), Nongaap R&d And Sg&a Expenses (which Excludes Noncash Stockbased Compensation Expense). Management Uses This Measure When Assessing And Identifying Operational Trends And, In Management’s Opinion, This Nongaap Measure Is Useful To Investors And Other Users Of Its Financial Statements By Providing Greater Transparency Into The Historical And Projected Operating Performance Of The Company And The Company’s Future Outlook. Nongaap Financial Measures Are Not An Alternative For Financial Measures Prepared In Accordance With Gaap, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2026
I q eng
2025
I q eng
III q eng
IV q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300UJLWOIWFDGB318
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001070081
  • EIN
    04-3416587
Registration is required to get access.